Sunscreens and Photoprotection BASIC and CLINICAL DERMATOLOGY

Total Page:16

File Type:pdf, Size:1020Kb

Sunscreens and Photoprotection BASIC and CLINICAL DERMATOLOGY Job#: 302626p Date: 08-11-29 11:12:57 Dermatology Clinical about the book… Designed with practicing dermatologists, dermatology trainees, physicians, and scientists interested in photoprotection in mind, this concise and highly illustrated guide provides the latest knowledge of photoprotection in dermatology and cosmetic science. Clinical Guide to Sunscreens and Guide Photoprotection also addresses recent important international and domestic regulatory activity and requirements on the use of novel sun protective chemicals and proper labeling of products to ensure increased consumer awareness. Clinical Guide to This concisely written, problem-oriented text explores: • the biologic and clinical effects of ultraviolet (UV) radiation, erythema, to delayed tanning, photoimmunosuppression, photoaging, and photocarcinogenesis • the biologic and clinical effects of the spectrum of UV radiation on disease and Sunscreens disease progression Sunscreens and • current knowledge and awareness of the protective effects of sunscreens and UVB/UVA protection, and the latest research on more effective UV filters and oral photoprotective agents • newly recognized agents and supplements of photoprotection, such as clothing, window glass, contact lenses, and sunglasses Photoprotection • areas of present photoprotection research, including novel delivery systems, topical antioxidants, and technology used for sunless tan simulation and about the editors... HENRY W. LIM is Chairman and C.S. Livingood Chair of the Department of Dermatology, Henry Ford Hospital; Senior Vice President for Academic Affairs, Henry Ford Health System; and Professor of Photoprotection Edited by Pathology and Associate Dean for Henry Ford Health System, Wayne State University School of Medicine, Detroit, Michigan, USA. Dr. Lim has served as Vice President of the American Academy of Dermatology and is a current Director of the American Board of Dermatology. He is an Associate Henry W. Lim Editor of the Journal of Investigative Dermatology, a Section Editor of the Journal of Dermatological Sciences, and was Editor-in-Chief of Photodermatology, Photoimmunology, and Photomedicine. He is an elected honorary member of dermatology organizations in Austria, the Philippines, and China. Zoe Diana Draelos Dr. Lim is the editor of three other Informa Healthcare titles: Clinical Photomedicine; Photoaging; and Photodermatology. He received his M.D. from SUNY Downstate Medical Center, Brooklyn, New York, USA. ZOE DIANA DRAELOS is a board certified dermatologist in private practice and a Primary Investigator for Dermatology Consulting Services, High Point, North Carolina, USA. She founded Dermatology Consulting Services in 1988 to provide education, develop formulation technology, and conduct clinical studies in association with the pharmaceutical and cosmetics industry. A national and international speaker, Dr. Draelos has been the recipient of numerous research grants and served as Principal Investigator on more than 200 clinical trials. She has also contributed more than 200 articles and 25 book chapters, and is the author and editor of two Informa Healthcare titles, Hair Care and Draelos Cosmeceuticals, respectively. She serves on eight editorial boards, including Cosmetics & Toiletries and Lim The International Journal of Cosmetic Science, and is Editor in Chief of the Journal of Cosmetic Dermatology. • Dr. Draelos is a fellow of the American Academy of Dermatology and a member of the American Dermatological Association and the Society for Investigative Dermatology, among many others. She has been the recipient of several awards and honors, including a Lifetime Achievement Award for her research from Health Beauty America. H8084 Printed in the United States of America Clinical Guide to Sunscreens and Photoprotection BASIC AND CLINICAL DERMATOLOGY Series Editors Alan R. Shalita, M.D. Distinguished Teaching Professor and Chairman Department of Dermatology SUNY Downstate Medical Center Brooklyn, New York David A. Norris, M.D. Director of Research Professor of Dermatology The University of Colorado Health Sciences Center Denver, Colorado 1. Cutaneous Investigation in Health and Disease: Noninvasive Methods and Instrumentation, edited by Jean-Luc Leveˆque 2. Irritant Contact Dermatitis, edited by Edward M. Jackson and Ronald Goldner 3. Fundamentals of Dermatology: A Study Guide, Franklin S. Glickman and Alan R. Shalita 4. Aging Skin: Properties and Functional Changes, edited by Jean-Luc Leveˆque and Pierre G. Agache 5. Retinoids: Progress in Research and Clinical Applications, edited by Maria A. Livrea and Lester Packer 6. Clinical Photomedicine, edited by Henry W. Lim and Nicholas A. Soter 7. Cutaneous Antifungal Agents: Selected Compounds in Clinical Practice and Development, edited by John W. Rippon and Robert A. Fromtling 8. Oxidative Stress in Dermatology, edited by Ju¨rgen Fuchs and Lester Packer 9. Connective Tissue Diseases of the Skin, edited by Charles M. Lapie`re and Thomas Krieg 10. Epidermal Growth Factors and Cytokines, edited by Thomas A. Luger and Thomas Schwarz 11. Skin Changes and Diseases in Pregnancy, edited by Marwali Harahap and Robert C. Wallach 12. Fungal Disease: Biology, Immunology, and Diagnosis, edited by Paul H. Jacobs and Lexie Nall 13. Immunomodulatory and Cytotoxic Agents in Dermatology, edited by Charles J. McDonald 14. Cutaneous Infection and Therapy, edited by Raza Aly, Karl R. Beutner, and Howard I. Maibach 15. Tissue Augmentation in Clinical Practice: Procedures and Techniques, edited by Arnold William Klein 16. Psoriasis: Third Edition, Revised and Expanded, edited by Henry H. Roenigk, Jr., and Howard I. Maibach 17. Surgical Techniques for Cutaneous Scar Revision, edited by Marwali Harahap 18. Drug Therapy in Dermatology, edited by Larry E. Millikan 19. Scarless Wound Healing, edited by Hari G. Garg and Michael T. Longaker 20. Cosmetic Surgery: An Interdisciplinary Approach, edited by Rhoda S. Narins 21. Topical Absorption of Dermatological Products, edited by Robert L. Bronaugh and Howard I. Maibach 22. Glycolic Acid Peels, edited by Ronald Moy, Debra Luftman, and Lenore S. Kakita 23. Innovative Techniques in Skin Surgery, edited by Marwali Harahap 24. Safe Liposuction and Fat Transfer, edited by Rhoda S. Narins 25. Pyschocutaneous Medicine, edited by John Y. M. Koo and Chai Sue Lee 26. Skin, Hair, and Nails: Structure and Function, edited by Bo Forslind and Magnus Lindberg 27. Itch: Basic Mechanisms and Therapy, edited by Gil Yosipovitch, Malcolm W. Greaves, Alan B. Fleischer, and Francis McGlone 28. Photoaging, edited by Darrell S. Rigel, Robert A. Weiss, Henry W. Lim, and Jeffrey S. Dover 29. Vitiligo: Problems and Solutions, edited by Torello Lotti and Jana Hercogova 30. Photodamaged Skin, edited by David J. Goldberg 31. Ambulatory Phlebectomy, Second Edition, edited by Mitchel P. Goldman, Mihael Georgiev, and Stefano Ricci 32. Cutaneous Lymphomas, edited by Gunter Burg and Werner Kempf 33. Wound Healing, edited by Anna Falabella and Robert Kirsner 34. Phototherapy and Photochemotherapy for Skin Disease, Third Edition, Warwick L. Morison 35. Advanced Techniques in Dermatologic Surgery, edited by Mitchel P. Goldman and Robert A. Weiss 36. Tissue Augmentation in Clinical Practice, Second Edition, edited by Arnold W. Klein 37. Cellulite: Pathophysiology and Treatment, edited by Mitchel P. Goldman, Pier Antonio Bacci, Gustavo Leibaschoff, Doris Hexsel, and Fabrizio Angelini 38. Photodermatology, edited by Henry W. Lim, Herbert Ho¨nigsmann, and John L. M. Hawk 39. Retinoids and Carotenoids in Dermatology, edited by Anders Vahlquist and Madeleine Duvic 40. Acne and Its Therapy, edited by Guy F. Webster and Anthony V. Rawlings 41. Hair and Scalp Diseases: Medical, Surgical, and Cosmetic Treatments, edited by Amy J. McMichael and Maria K. Hordinsky 42. Anesthesia and Analgesia in Dermatologic Surgery, edited by Marwali Harahap and Adel R. Abadir 43. Clinical Guide to Sunscreens and Photoprotection, edited by Henry W. Lim and Zoe Diana Draelos Clinical Guide to Sunscreens and Photoprotection Edited by Henry W. Lim Henry Ford Hospital Detroit, Michigan, USA Zoe Diana Draelos Dermatology Consulting Services High Point, North Carolina, USA [ram][D:/informa_Publishing/H8084_Lim_112080/z_production/z_3B2_3D_files/978-1-4200- 8084-1_CH0000_O.3d] [4/11/08/21:53:30] [1–12] Informa Healthcare USA, Inc. 52 Vanderbilt Avenue New York, NY 10017 # 2009 by Informa Healthcare USA, Inc. Informa Healthcare is an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10987654321 International Standard Book Number-10: 1-4200-8084-9 (Hardcover) International Standard Book Number-13: 978-1-4200-8084-1 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequence of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please
Recommended publications
  • A Thesis Entitled Evaluating UVB and UVA Boosting Technologies For
    A Thesis entitled Evaluating UVB and UVA Boosting Technologies for Chemical and Physical Sunscreens by An Ngoc Hiep Huynh Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences Industrial Pharmacy ___________________________________________ Gabriella Baki, Ph.D., Committee Chair ___________________________________________ Jerry Nesamony, Ph.D., Committee Member ___________________________________________ Matthew W. Liberatore, Ph.D., Committee Member ___________________________________________ Dr. Amanda C. Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo May 2020 Copyright 2020 An Ngoc Hiep Huynh This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Evaluating UVB and UVA Boosting Technologies for Chemical and Physical Sunscreens by An Ngoc Hiep Huynh Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences Industrial Pharmacy The University of Toledo May 2020 There are currently 14 organic and 2 inorganic UV filters approved in the United States. Due to coral reef safety concerns, octinoxate and oxybenzone have been banned in Hawaii, Key West, FL and the US Virgin Islands; and octocrylene is also being studied for its potential impact on coral reef safety, leaving 11 organic UV filters as viable options for sunscreen manufacturers – with limitations on their combination. Since consumers are always looking for sunscreens with high SPF and broad-spectrum protection, the need for UVB and UVA protection boosting technologies is greater than ever. In a preliminary study, about two dozen emollients were scanned for their SPF boosting capability with selected organic UV filters.
    [Show full text]
  • GAO-18-61, SUNSCREEN: FDA Reviewed Applications For
    United States Government Accountability Office Report to Congressional Committees November 2017 SUNSCREEN FDA Reviewed Applications for Additional Active Ingredients and Determined More Data Needed GAO-18-61 November 2017 SUNSCREEN FDA Reviewed Applications for Additional Active Ingredients and Determined More Data Needed Highlights of GAO-18-61, a report to congressional committees Why GAO Did This Study What GAO Found Using sunscreen as directed with other The Food and Drug Administration (FDA), within the Department of Health and sun protective measures may help Human Services, implemented requirements for reviewing applications for reduce the risk of skin cancer—the sunscreen active ingredients within time frames set by the Sunscreen Innovation most common form of cancer in the Act, which was enacted in November 2014. For example, the agency issued a United States. In the United States, guidance document on safety and effectiveness testing in November 2016. sunscreen is considered an over-the- counter drug, which is a drug available As of August 2017, all applications for sunscreen active ingredients remain to consumers without a prescription. pending after the agency determined more safety and effectiveness data are Some sunscreen active ingredients not needed. By February 2015, FDA completed its initial review of the safety and currently marketed in the United States effectiveness data for each of the eight pending applications, as required by the have been available in products in act. FDA concluded that additional data are needed to determine that the other countries for more than a ingredients are generally recognized as safe and effective (GRASE), which is decade. Companies that manufacture needed so that products using the ingredients can subsequently be marketed in some of these ingredients have sought the United States without FDA’s premarket approval.
    [Show full text]
  • Octinoxate, Octisalate, Avobenzone, Ensulizole, Homosalate
    TONYMOLY MAGIC FOOD MANGO MILD SUN BLOCK- octinoxate, octisalate, avobenzone, ensulizole, homosalate cream TONYMOLY CO.,LTD Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. ---------- ACTIVE INGREDIENT Active ingredients: Ethylhexyl Methoxycinnamate 6.9%, Ethylhexyl Salicylate 4.5%, Butyl Methoxydibenzoylmethane 3.5%, Phenylbenzimidazole Sulfonic Acid 3.5%, Homosalate 3.0% INACTIVE INGREDIENT Inactive ingredients: Water, Butylene Glycol, Alcohol Denat., Octocrylene, Phenethyl Benzoate, Aminomethyl Propanol, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, Triceteareth-4 Phosphate, Glycol Stearate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Carbomer, PEG-2 Stearate, Fragrance(Parfum), Phenoxyethanol, Glyceryl Caprylate, Caprylyl Glycol, Mangifera Indica (Mango) Seed Butter, Disodium EDTA, Citrus Limon (Lemon) Fruit Extract, Musa Sapientum (Banana) Fruit Extract, Propylene Glycol, 1,2-Hexanediol, Citrus Aurantium Dulcis (Orange) Fruit Extract, Mangifera Indica (Mango) Fruit Extract, Psidium Guajava Fruit Extract, Citrus Paradisi (Grapefruit) Fruit Extract, Cocos Nucifera (Coconut) Fruit Extract, Actinidia Chinensis (Kiwi) Fruit Extract, Carica Papaya (Papaya) Fruit Extract, Ethylhexylglycerin PURPOSE Purpose: Sunscreen WARNINGS Warnings: For external use only Do not use on damaged or broken skin Stop use and ask a doctor if irritation occurs Keep out of reach of children DESCRIPTION Uses: - helps prevent sunburn - If used as directed with other sun protection measures Directions: decreases the risk of skin cancer and early skin aging caused by the sun Directions: For sunscreen use: - apply liberally 15 minutes before sun exposure - use a water resistant sunscreen if swimming or sweating - reapply at least every 2 hours - Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging.
    [Show full text]
  • Sun Lotion Chemicals As Endocrine Disruptors
    HORMONES 2015, 14(1):32-46 Review Sun lotion chemicals as endocrine disruptors Sotirios Maipas, Polyxeni Nicolopoulou-Stamati National and Kapodistrian University of Athens, School of Medicine, First Department of Pathology and Cytology Unit, 1st Pathology Laboratory, Athens, Greece Both authors contributed equally to this work ABSTRACT Ultraviolet solar radiation is a well-known environmental health risk factor and the use of sun lotions is encouraged to achieve protection mainly from skin cancer. Sun lotions are cosmetic commercial products that combine active and inactive ingredients and many of these are associated with health problems, including allergic reactions and endocrine disorders. This review focuses on their ability to cause endocrine and reproductive impairments, with empha- sis laid on the active ingredients (common and less common UV filters). In vitro and in vivo studies have demonstrated their ability to show oestrogenic/anti-oestrogenic and androgenic/ anti-androgenic activity. Many ingredients affect the oestrous cycle, spermatogenesis, sexual behaviour, fertility and other reproductive parameters in experimental animals. Their presence in aquatic environments may reveal a new emerging environmental hazard. Key words: Active ingredients, Endocrine disruptors, Environmental hazard, Reproductive impair- ments, Sun creams, Sun lotions, Sunscreens, UV filters 1. INTRODUCTION ing, but the level of photoprotection is insufficient to prevent the harmful effects of UV radiation.3,4 Ultraviolet (UV) solar radiation is one
    [Show full text]
  • Table 1 - Experimental and Predicted Physical-Chemical Parameters of the Most Recently Investigated UV-Absorbers
    Table 1 - Experimental and predicted physical-chemical parameters of the most recently investigated UV-absorbers. INCI name (INN/XAN) Chemical structure Brand name Absorption Molecula LogP Water solubility Melting spectrum range r weight (mg/L) point (°C) (g/mol)4 diethylamino Uvinul® A Plus UVA1 5.7-6.21 <0.01 (20°C) 1 54; 314 hydroxybenzoyl hexyl 397.515 (dec.) 1 benzoate Butyl Eusolex® 9020, UVA 310.393 4.514 2.2 (25°C)4 83.54 methoxydibenzoylmetha Parsol® 1789 ne (avobenzone) 4-methylbenzylidene Eusolex® 6300 UVB 258.397 4.95 1.3 (20°C) 66–68 camphor (enzacamene) Parsol® 5000 Uvinul® MBC 95 Octocrylene Eusolex® OCR, UVB 361.485 6.783 0.00383 N/A (octocrilene) Parsol® 340, Uvinul® N539T, NeoHeliopan® 303 USP isoamyl p- Neo Heliopan® UVB 248.322 3.61 4.9 (25°C)1 N/A methoxycinnamate E1000 (amiloxate) Ethylhexyl triazone Uvinul® T150 UVB 823.092 > 7(20 °C) 6 < 0.001 (20.0 °C) 6 1296 Ethylhexyl Parsol® MCX, UVB 290.403 6.14 0.041 (24 °C and N/A methoxycinnamate Heliopan® New pH 7.1) 4 (octinoxate) Ethylhexyl dimethyl Escalol™ 507 UVB 277.4084 5.774 0.54 (25 °C) 4 N/A PABA (padimate-O) Arlatone 507 Eusolex 6007 benzophenone-3 Eusolex® 4360 UVA2+ UVB 228.247 3.72 3.7 (20°C) 2 62-652 (oxybenzone) bis-ethylhexyloxyphenol Tinosorb® S UVA1+UVB 627.826 12.61 <10-4 80.401 methoxyphenol triazine (bemotrizinol) Phenylbenzimidazole Eusolex® 232 UVA2+ UVB 274.2945 -1.1 (pH 5) > 30% (As sodium N/A sulfonic acid Parsol® HS -2.1 (pH 8)5 or (ensulizole) Neo Heliopan® triethanolammoniu Hydro m salt at 20°C) 5 1 (3) 2 (34) 3 (44) 4 Pubchem 5 SCCP/1056/06 Opinion on phenylbenzimidazole sulfonic acid and its salts 6 BASF safety data sheet Table 2 – In vitro studies for the assessment of skin permeation/penetration of sunscreens.
    [Show full text]
  • Photophysics and Skin Penetration of Active Agents in a Commercial Sunscreen and Insect Repellent
    PHOTOPHYSICS AND SKIN PENETRATION OF ACTIVE AGENTS IN A COMMERCIAL SUNSCREEN AND INSECT REPELLENT by DONALD PRETTYPAUL A Dissertation submitted to the Graduate School-Newark Rutgers, The State University of New Jersey In partial fulfillment of the requirements for the degree of Doctor of Philosophy Graduate Program in Chemistry written under the direction of Professor Richard Mendelsohn Professor Piotr Piotrowiak and approved by Newark, New Jersey October 2018 ©2018 Donald Prettypaul ALL RIGHTS RESERVED ABSTRACT OF DISSERTATION PHOTOPHYSICS AND SKIN PENETRATION OF ACTIVE AGENTS IN A COMMERCIAL SUNSCREEN AND INSECT REPELLENT By DONALD PRETTYPAUL Dissertation co-Directors: Professor Richard Mendelsohn Professor Piotr Piotrowiak This dissertation is focused on active agents in commercial sunscreen and insect repellent products. It consists of two parts, the first focusing on the photophysics of a sunscreen active agent and the second on the permeation and spatial distribution of the sunscreen active and an insect repellent active when these agents are applied to ex-vivo human skin. In the photochemistry study, ultrafast spectroscopy was used to study the excited state dynamics of the sunscreen molecule, Bemotrizinol. The work focused on the dissipation rates of the electronic excitation energy in different solvents. To complement the results from time-resolved femtosecond spectroscopy, Hartree- Fock UH/UHF 6-31G* calculations were used to characterize the ground and excited states potential energy surfaces. The results indicate that the excited state deactivation pathway follows a proton coupled electron transfer process which ii proceeds via a concerted mechanism. The dependencies on solvent polarity, viscosity, and H/D isotope effects, were investigated. Sunscreen products have been developed to protect skin from ultraviolet (UV) radiation; to achieve adequate protection, the sunscreen must be evenly applied and remain on the surface of the skin.
    [Show full text]
  • Technical Appendix to the Sunscreen Proposed Rule
    DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Technical Appendix to the Sunscreen Proposed Rule 1 Table of Contents I. Overview ................................................................................................................................. 3 A. Definitions ........................................................................................................................ 3 II. Sunscreen Product Counts ...................................................................................................... 4 A. Sunscreen Product Search ................................................................................................ 4 B. Private Label Products ..................................................................................................... 6 C. Sunscreen Firms and Manufacturers ................................................................................ 7 D. Number of Relabeled and Reformulated Units ................................................................ 9 1. Relabeled Units............................................................................................................. 9 2. Reformulated Units....................................................................................................... 9 III. Sales by Product ................................................................................................................. 10 A. Total Market Sales ........................................................................................................
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • New Technology Provides Cosmetically Elegant Photoprotection Zoe Diana Draelos, MD; Christian Oresajo; Margarita Yatskayer; Angelike Galdi; Isabelle Hansenne
    COSMETIC CONSULTATION New Technology Provides Cosmetically Elegant Photoprotection Zoe Diana Draelos, MD; Christian Oresajo; Margarita Yatskayer; Angelike Galdi; Isabelle Hansenne he primary preventable cause of photoaging is United States, as there is no official rating system for exposure to UVA radiation. This wavelength UVA photoprotection yet. T emitted by the sun is present year round in all Ecamsule absorbs UVA radiation in the range of 320 to latitudes. Currently, the majority of sun-protective prod- 360 nm, but its peak absorbance occurs at 345 nm. It is ucts provide excellent UVB protection with minimal UVA typically combined with other organic sunscreen ingredi- protection. Although UVB protection is important in ents, such as avobenzone and octocrylene. Avobenzone, order to prevent sun damage to the skin from occurring, which is a photounstable photoprotectant, becomes UVA protection is equally important. New developments photostable when combined with octocrylene. These in raw material science have led to the manufacture of ingredients yield a photostable broad-spectrum sunscreen novel ingredients able to provide unprecedented photo- combination. However, the active sunscreen agents are protection COSin the UVA spectrum. DERMonly part of the formulation. Also important in sunscreen One of the most significant developments in cutaneous is the construction of the vehicle to deliver the photo- UVA protection was the discovery of ecamsule (Figure 1), protectants in an aesthetically pleasing manner, enticing also known as Mexoryl SX. Mexoryl SX, which has patients to wear the product. Sunscreens fail to be effec- the International Nomenclature of Cosmetic Ingredients tive if they remain in the bottle. name of terephthalylidene dicamphor sulfonic acid, is In order to evaluate the efficacy and tolerability of a water soluble.
    [Show full text]
  • 1. Background and Action Requested
    June 27, 2019 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Comments Submitted to Docket No. 1978N-0018 (Formerly Docket No. FDA–1978–N– 0038) for “Sunscreen Drug Products for Over-the-Counter Human Use,” Regulatory Information No. 0910-AF43 DSM Nutritional Products LLC (“DSM”) is pleased to provide the following comments in response to the Food and Drug Administration’s (FDA’s) Tentative Final Monograph (“TFM”) for Sunscreen Drug Products Over-the-Counter (OTC) Human Use, published at 84 Fed. Reg. 6204 (February 26, 2019). As a global science-based company active in Nutrition, Health and Sustainable Living, DSM is a world leading supplier of vitamins, feed, food, pharmaceutical, cosmetic, personal care and aroma ingredients. In sunscreens, DSM is a leading world-wide provider of numerous UV filters, including Avobenzone. DSM takes human health and safety very seriously and believes that sunscreens are proven and effective interventions that help provide consumer protection against skin cancers and skin damage caused by the sun’s rays. DSM is committed to proactively supporting the safety and availability of existing and new sunscreen active ingredients that help protect public health. DSM requests that FDA modify its proposed rule taking into consideration the comments provided herein. 1. Background and Action Requested Skin cancer is a significant, and largely preventable, public health concern. Sunscreens have been widely and safely used by the general public for their photoprotective properties, including prevention of photocarcinogenesis and photoaging and management of photodermatoses for more than 40 years. FDA’s Sunscreen Monograph rule has identified the permitted active ingredients (UV-filters) for sunscreens since 1978.
    [Show full text]
  • Sunscreen Faqs
    Sunscreen FAQs What type of sunscreen should I use? There are two main types of sunscreen ingredients: physical sun blockers and chemical sunscreens. Physical sunscreens prevent ultraviolet light from reaching your skin, and contain either zinc oxide or titanium dioxide. Physical sunscreens protect against UVA and UVB damage. Physical sunscreens are preferred for patients with sensitive skin or children. Chemical sunscreens rely on an interaction between the sun and the chemical to protect your skin. Examples of such chemicals are avobenzone, octinoxate, homosalate, padimate O, and many others. Chemical sunscreens can protect against UVA, UVB, or both types of damage, depending on which ingredient is used. Read the label to ensure coverage for both UVA and UVB exposure. There are new ingredients being developed that take chemical sunscreens and stabilize them to prolong their activity (i.e., Helioplex, Mexoryl). Does the SPF really matter? In laboratory testing, there are minor differences between SPF 15 and SPF 30 or greater products. However, that data is based on using 1 oz. (30 gm.) of sunscreen for each full body application (the size of a shot glass). Most people use far less in real-life settings. For that reason, we recommend an SPF of at least 30. It is common to find good sunscreens with SPF ranging from 45-70. To maintain protection, reapply sunscreen every 1-3 hours, depending on sweating, water exposure, and sun intensity. Is sunscreen alone enough to protect my skin in the sun? In some cases, yes. However, if you are in the sun for longer periods on a regular basis (such as gardening, golfing, boating, sports), it may be better to add sun protective clothing or habits.
    [Show full text]
  • WO 2013/036901 A2 14 March 2013 (14.03.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/036901 A2 14 March 2013 (14.03.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 8/30 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/054376 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 10 September 2012 (10.09.2012) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/532,701 9 September 201 1 (09.09.201 1) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): UNIVER¬ kind of regional protection available): ARIPO (BW, GH, SITY OF FLORIDA RESEARCH FOUNDATION, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, INC.
    [Show full text]